October 12, 2021
Accelerating Drug Discovery and Development with Flow Cytometry
In this post, we discuss modern flow cytometry as a game-changer for cell functional assays, immune monitoring, and function-based screening of drug candidates to support and accelerate your biomarker strategy and translational programs.
LEARN MORE
September 14, 2021
Accelerating Cancer Drug Discovery with Digital Pathology-Based Biomarker Analysis
Digital pathology is an innovative technology that is transforming the field of modern pathology.
LEARN MORE
September 1, 2021
In Vitro Potency Assays for Assessing the Function of anti-PD-1 Checkpoint Inhibitors
In this post we explore the different in vitro potency assays for assessing the function of anti-PD-1 checkpoint ...
LEARN MORE
August 16, 2021
Next-Generation Sequencing in Cell Line and Biosample Authentication
While the authentication of biosamples (i.e., cell lines, organoids, xenograft and homograft models) has long been ...
LEARN MORE
August 2, 2021
In vivo preclinical models for immune-mediated inflammatory disease drug development
In this blog we will explore immune-mediated inflammatory diseases (IMIDs)—which represent a diverse group of ...
LEARN MORE
July 5, 2021
Preclinical Models for Bispecific T Cell Engager Development
Last month we hosted a webinar with Dr. Ludovic Bourré, Senior Director of Scientific Engagement at CrownBio, focused ...
LEARN MORE
June 1, 2021
Ask the Expert: Organoid and Immune Cell Co-Cultures
Dr Yujun Huang, Senior Director Immuno-Oncology at CrownBio, answers the most popular questions from his recent organoids and immune cell co-cultures webinar, covering how to investigate tumor-antigen specific immune cell reactivity and optimal applications for a tumor organoid co-culture platform.
LEARN MORE
May 4, 2021
For the Children: Advancing the Cause of Pediatric Cancer Research
Why are cancer treatments for children lagging behind the latest advancements in clinical oncology? CrownBio Director ...
LEARN MORE
April 1, 2021
Expanding the Horizon of Antibody-Drug Conjugates for Cancer Treatment
This post explores the fast-expanding topic of antibody-drug conjugates (ADCs), including those that have been approved ...
LEARN MORE
March 1, 2021
Profiling of Tumor-Infiltrating Immune Cells in Syngeneic Tumor Models to Support Drug Development
Tumor-Infiltrating Immune Cells: Explore how the identification and quantification of tumor-infiltrating lymphocytes ...
LEARN MORE
December 18, 2020
Factors to Consider When Selecting a Next Generation Sequencing (NGS) Technology
Explore the main factors you need to consider before choosing and using next generation sequencing (NGS).
LEARN MORE
December 16, 2020
Germ-Free or Antibiotic-Treated Mice? Which Model for Studying the Role of the Gut Microbiota in Preclinical Studies
Explore the differences and similarities of germ-free (GF) and antibiotic-treated mice as models for studying the role ...
LEARN MORE
December 3, 2020
The Latest Developments on PARP Inhibitors for Prostate Cancer Treatment
Review the status of PARP inhibitors (PARPi) for prostate cancer treatment, with a focus on recent developments in drug ...
LEARN MORE
November 30, 2020
The Rising Importance of GITR Agonists as Alternative I/O Candidates for Combination Drug Strategies
Explore why glucocorticoid-induced TNFR-related protein (GITR or CD357) agonists are becoming increasingly important as ...
LEARN MORE
November 10, 2020
SHP2 and SOS1 Targets: Additional Players in the KRAS Inhibitors Race?
Explore why upstream KRAS-mutant targets, such as SHP2 and SOS1, may lead to optimized therapeutic combinations for ...
LEARN MORE
